Transgene expression is transient in non-integrating lentiviral-based transduction system: an alternative approach for safety gene therapy application

K E Y W O R D S Published online: 5 June, 2014 *Corresponding Author: Fazlina Nordin Email: nordinf@ppukm.ukm.edu. my Lentiviral vectors have been extensively analysed and used for clinical gene therapy application. The transduction efficiency is attributable by integration into the target cell genome which carries the risk of insertional mutagenesis, thus can lead to malignant transformation. Non-integrating lentiviral vector (NILV) is produced through mutation in the integrase enzymes to interrupt viral RNA integration in the host genome. However, the transgene expression remains episomal which minimized the genomic alteration.